Psychedelics have re-emerged as promising therapeutics for neuropsychiatric disorders, including depression, anxiety, post-traumatic stress disorder, and substance use disorders. While their beneficial effects are largely attributed to serotonin 2A (5-HT2A) receptor activation, psychedelics exhibit substantial diversity in chemical structure, receptor binding kinetics, metabolism, and duration...
Please don't use dangerous characters * Last Name Please don't use dangerous characters * Email Address Please enter a email address * Comments Please don't use dangerous characters * Security code The entered code is invalid. Generate New Image Type the code from the image Abstract View: 388 Your browser does not support the canvas element. yearsJanFebMarAprMayJunJulAugSepOctNovDec...
BACKGROUND: Mu opioid receptor (MOR) agonists are the primary medication class used to treat moderate to severe pain; however, the ongoing opioid overdose crisis underscores the need for alternatives to MOR agonists for pain treatment. Delta9-tetrahydrocannabinol (THC), a cannabinoid CB1 receptor (CB1R) agonist, and sigma1 receptor (σ1R) antagonists elicit antinociceptive effects albeit less...